Mobile

A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY OR...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020475-23

A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY ORAL ADMINISTRATION OF A 5-LIPOXYGENASE (5-LO) INHIBITOR PF-04191834 ALONE AND IN COMBINATION WITH NAPROXEN IN PATIENTS WITH FLARE-ENRICHED OSTEOARTHRITIS OF THE KNEE

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

- To evaluate the efficacy of PF-04191834 versus placebo in relieving pain in patients with osteoarthritis of the knee. - To evaluate the efficacy of PF-04191834 plus naproxen versus naproxen in relieving pain in patients with osteoarthritis of the knee. - To evaluate the safety and tolerability of PF-04191834 (as monotherapy) in patients with osteoarthritis. - To evaluate the safety and tolerability of PF-04191834 when co-administered with naproxen in patients with osteoarthritis.

Critère d'inclusion

  • Chronic pain in patients with Osteo-arthritis

Liens